CINECA IRIS Institutional Research Information System

LOLLI, Marco Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.511
EU - Europa 4.380
AS - Asia 1.299
AF - Africa 58
SA - Sud America 47
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 8
Totale 11.320
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.351
IT - Italia 1.593
CN - Cina 620
IE - Irlanda 539
SE - Svezia 439
DE - Germania 434
GB - Regno Unito 290
FR - Francia 250
UA - Ucraina 203
AT - Austria 154
VN - Vietnam 154
CA - Canada 145
IN - India 139
FI - Finlandia 131
KR - Corea 80
HK - Hong Kong 61
PL - Polonia 61
JP - Giappone 57
BE - Belgio 47
DK - Danimarca 47
SG - Singapore 40
NL - Olanda 32
RO - Romania 32
IR - Iran 29
SN - Senegal 26
TW - Taiwan 24
BR - Brasile 23
ES - Italia 18
AU - Australia 17
NG - Nigeria 17
TR - Turchia 17
CZ - Repubblica Ceca 16
PK - Pakistan 15
RU - Federazione Russa 15
CH - Svizzera 14
GR - Grecia 14
PT - Portogallo 14
ID - Indonesia 13
MY - Malesia 13
CO - Colombia 9
MX - Messico 9
AR - Argentina 8
EU - Europa 8
HR - Croazia 6
IQ - Iraq 6
UZ - Uzbekistan 6
BG - Bulgaria 5
BZ - Belize 5
MA - Marocco 5
NO - Norvegia 5
PH - Filippine 5
SK - Slovacchia (Repubblica Slovacca) 5
TH - Thailandia 5
CI - Costa d'Avorio 4
CL - Cile 4
MO - Macao, regione amministrativa speciale della Cina 4
AE - Emirati Arabi Uniti 3
EG - Egitto 3
RS - Serbia 3
SI - Slovenia 3
ZA - Sudafrica 3
GE - Georgia 2
HU - Ungheria 2
IL - Israele 2
LU - Lussemburgo 2
MK - Macedonia 2
MT - Malta 2
SA - Arabia Saudita 2
UY - Uruguay 2
BD - Bangladesh 1
BO - Bolivia 1
CU - Cuba 1
EE - Estonia 1
LV - Lettonia 1
SY - Repubblica araba siriana 1
Totale 11.320
Salva come PNG Salva come JPEG
Città #
Chandler 820
Dublin 532
Torino 358
Ann Arbor 327
Fairfield 289
Beijing 275
Houston 241
Nyköping 220
Woodbridge 207
Jacksonville 201
Ashburn 198
Turin 180
Vienna 153
Wilmington 151
Medford 140
Seattle 137
Princeton 127
Dong Ket 123
Los Angeles 121
Villeurbanne 118
Dearborn 117
Redwood City 108
Cambridge 107
Frankfurt am Main 84
Pisa 82
Fremont 75
Milan 72
Ottawa 58
Munich 50
Warsaw 49
Boston 47
Nanjing 45
Guangzhou 39
Brussels 37
Shanghai 35
Copenhagen 34
Rome 32
New York 31
Toronto 28
Hangzhou 27
Horia 26
San Diego 23
Washington 23
Boardman 22
Hefei 21
Norwalk 21
Québec 21
Helsinki 15
Abuja 14
Chengdu 14
Delhi 14
Paris 14
Piemonte 14
Menlo Park 13
Tokyo 13
Bradford 12
Central 12
Leinì 12
Singapore 12
Verona 12
West Jordan 12
Florence 11
Modena 11
Padova 11
Rivoli 11
Taipei 11
Ypsilanti 11
Braunschweig 10
Jakarta 10
Leeds 10
Bari 9
Gunzenhausen 9
Hebei 9
Jinan 9
Kuala Lumpur 9
Mountain View 9
Naples 9
Phoenix 9
Siena 9
Alpignano 8
Amsterdam 8
Buffalo 8
Catanzaro 8
Chennai 8
Duncan 8
Falls Church 8
Hamburg 8
Lisbon 8
Lucknow 8
Novara 8
Pune 8
Tai Wan 8
Taichung 8
Viterbo 8
Birmingham 7
Kunming 7
Lachine 7
Monmouth Junction 7
Mumbai 7
Nürnberg 7
Totale 6.754
Salva come PNG Salva come JPEG
Nome #
1,2,5-Oxadiazole analogues of leflunomide and related compounds 428
Nuovi inibitori della diidroorotato deidrogenasi umana (hDHODH) e loro uso mirato sul differenziamento mieloide 418
Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention 316
NOVEL HUMAN DIHYDROOROTATE DEHYDROGENASE (HDHODH) INHIBITORS AND THEIR USE IN TARGETING ONCOLOGICAL DISEASES SENSITIVE TO PYRIMIDINE STARVATION 275
DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents 243
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 239
New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold 234
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 223
4-Hydroxy-1,2,5-oxadiazol-3-yl Moiety as Bioisoster of the Carboxy Function. Synthesis, Ionization Constants, and Molecular Pharmacological Characterization at Ionotropic Glutamate Receptors of Compounds Related to Glutamate and Its Homologues 188
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: Application of a bioisosteric scaffold hopping approach to flufenamic acid 185
Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches 165
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach 161
Multiple catalytic activities of human 17β-hydroxysteroid dehydrogenase type 7 respond differently to inhibitors. 158
Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds 153
The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors 152
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action 151
Recent advances in the synthesis of analogues of phytohormones strigolactones with ring-closing metathesis as a key step 150
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 149
A novel SWCNT platform bearing DOTA and b-cyclodextrin units. "One shot" multidecoration under microwave irradiation. 145
Design, synthesis, and biological evaluation of flufenamic acid derived bioisosteres as inhibitors of aldo-keto reductase 1C3 (AKR1C3) expressed in prostate cancer 144
Structure Activity Relationship of strigolactones via a novel, quantitative in planta bioassay 141
NEW HYDROXYAZOLES INHIBITORS OF ALDO-KETO REDUCTASE 1C3 (AKR1C3) OBTAINED BY SCAFFOLD HOPPING FROM FLUFENAMIC ACID AND INDOMETHACIN FOR CASTRATE RESISTANT PROSTATE CANCER 138
Searching for new NO-donor aspirin-like molecules: furoxanylacyl derivatives of salicylic acid and related furazans 126
Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs) 125
N-Acetyl-3-aminopyrazoles block the non canonical NF-kB cascade by selectively inhibiting NIK 117
MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells 114
PROBING THE BICYCLIC HYDROXYPYRAZOLO[1,5-a]PYRIDINE SCAFFOLD AS A CARBOXYLIC ACID BIOISOSTERE IN THE GABAa RECEPTOR SYSTEM 114
New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold 111
4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade 109
4-Hydroxy-1,2,3-triazole moiety as bioisostere of the carboxylic acid function: a novel scaffold to probe the orthosteric γ-aminobutyric acid receptor binding site 107
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3 106
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer 106
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 105
SAR STUDIES ON H2 ANTAGONISTS CONTAINING ALKYLAMINO SUBSTITUTED 1,2,5-THIADIAZOLE 1-OXIDE MOIETIES 102
TOWARD A BIOISOSTERIC ALKAEST – APPLICATION TO THE BIOISOSTERIC MODULATION OF IMD-0354 101
ONE -POT ALKOXYMERCURATION-BROMODEMERCURIATION: A VERSATILE ACCESS TO 3-ALKOXY-2-BROMOPROPANOIC ESTERS 100
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 100
Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies 98
Targeting Castration Resistant Prostate Cancer (CRPC) by innovative AKR1C3 inhibitors based on the 3-hydroxybenzoisoxazole structure 96
A new class of ibuprofen derivatives with reduced gastrotoxicity 95
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 95
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinity 94
Application of the arachno™ technology inside Educational fields: the introduction of parallel synthesis concepts inside an undergraduated lab 91
A differentiating and apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 91
Towards a Bioisosteric Alkaest: application to the bioisosteric modulation of IMD-0354 87
APPLICATION OF THE ARACHNO™ TECHNOLOGY FOR THE PARALLEL SYNTHESIS OF A LIBRARY OF ASPIRIN ANALOGUES 87
Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. A computational study on gamma-aminobutyric acid (GABA) related compounds 86
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by combination of in-silico ligand/structural pharmacophore models and scaffold hopping bioisosteric approaches 86
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentaatomic Heterocycles 85
Inibitori della diidroorotato deidrogenasi umana (hDHODH) per l'uso come antivirali 85
Discovery and optimization of new OvCHT1 inhibitors based on the 4-hydroxy-1H-1,2,3-triazole ring 82
1H-pyrazole-4-carboxylic acids active against Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH): discovery of a new scaffold for development of antimalarial agents 81
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold: SAR of the Biphenyl Moiety 81
Development of new hydroxypyrazole-based inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) 80
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer 77
Unsymmetrically substituted furoxants. 17. Structural investigations in benzenesulfonylfuroxan derivatives and related compounds 76
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase inhibitors 76
Targeting Human Onchocerciasis: Recent Advances Beyond Ivermectin 74
Synthesis and Structural Characterization of Regio Substituted 4-Hydroxy-1H-1,2,3-triazols as Possible Tool in Bioisosteric Applications 71
Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 71
Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin 70
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors 70
Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication 70
A differentiating and apoptotic therapy for acute myeloid leukaemia using potent human dihydroorotate dehydrogenase inhibitors. 69
Discovery of new NIK inhibitors by Structure-Based Drug Design 68
Design of new human Dihydroorotate Dehydrogenase inhibitors: amide bioisosterism in MEDS433 optimization 68
Design, synthesis and co-crystallization of new Plasmodium falciparum dihydroorotate dehydrogenase inhibitors based on hydroxypyrazole scaffold 66
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy 65
SUBSTITUTED 4-HYDROXY-1H-1,2,3-TRIAZOLES: SYNTHESIS AND BIOISOSTERIC APPLICATIONS 64
Heterocyclic ring cleavage upon collision-induced dissociation of deprotonated 3-hydroxy-1,2,5-oxadiazoles (3-hydroxyfurazans) 63
Five-Membered N-Heterocyclic Scaffolds as Novel Amino Bioisosteres at γ-Aminobutyric Acid (GABA) Type A Receptors and GABA Transporters 63
Probing the bicyclic hydroxypyrazolo[1,5-a]pyridine scaffold as a carboxylic acid bioisostere in theGABAA receptor system 60
Synthesis of new Gadolinium complexes for magnetic resonance imaging with improved relaxivity 60
Synthesis of labelled [N-15(3)]-6-bromopurine, a useful precursor of N-15-labelled O-6-alkylguanines, to be used as internal standards for quantitative GC-MS analyses 60
Improvement of in vivo pharmacokinetic profile of M433, a potent and innovative hDHODH inhibitor. 59
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 58
The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia 57
Design and synthesis of a library of pyrazolo[1,5-a]pyridine fluorophores for developing new fluorescent probes 57
SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF NOVEL AMINO BIOISOSTERES FOR THE GABAa RECEPTOR 56
Probing salicylamide bioisosteric replacement in the design of Plasmodium Falciparum dihydroorotate dehydrogenase (pfDHODH) inhibitors 55
Synthesis of new gadolinium complexes for magnetic resonance imaging with improved relaxivity 55
Hydroxypyrazolo[1,5-a]pyridine as a fluorescent carboxylic acid isostere: introducing GABAA receptor system affinities in the scaffold 52
Use of the 4-hydroxy-triazole moiety as a bioisosteric tool in the development of selective ligands for subtypes AMPA receptor 51
Detection of O6-Butylguanine and O6-(4-Hydroxybutyl)guanine in Urothelial and Hepatic DNA of Rats Given the Bladder Cancerogen N-Nitrosobutyl-(4-hydroxybutyl)amine 50
Synthesis of NO-Donor Bisphosphonates and Their in Vitro Action on Bone Resorption 50
Uses of the 4-hydroxy-1,2,5-oxadiazole-3-yl mojety as novel bioisoster of the carboxyl group 50
Synthesis of new Plasmodium Falciparum dihydroorotate dehydrogenase inhibitors through the application of an isosteric portfolio 49
New NO-donor Bisphosphonates 48
Regioselective N‐Alkylation of Ethyl 4‐Benzyloxy‐1,2,3‐triazolecarboxylate: A Useful Tool for the Synthesis of Carboxylic Acid Bioisosteres 48
The new generation hdhodh inhibitor meds433 hinders the in vitro replication of sars-cov-2 and other human coronaviruses [Calistri A.*, Luganini A.*, co-first author] 48
Urinary Excretion of O6-Butylguanine after the Administration of N-Nitroso-N-butylurea in Rats 47
NEW CLASS OF NO-DONORS WITH BONE SELECTIVITY 47
Exploring the intramolecular catalysis of the proton exchange process to modulate the relaxivity of Gd(iii)-complexes of HP-DO3A-like ligands 46
Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML) 46
Dihydroorotate dehydrogenase inhibitors in anti-infective drug research 46
Multiple-targeting ligands for AKR1C3 enzyme and androgen receptor to target prostate cancer 46
Apoptotic and differentiating therapy for AML using potent human dihydroorotate dehydrogenase inhibitor 45
Hydroxyazoles as acid isosteres and their drug design applications—Part 2: Bicyclic systems 44
Hydroxypyrazolol[1,5-a]pyridine as a fluorescent carboxylic acid isostere: development of new fluorescent 4-PHP analogues 43
Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with hydroxypyrazole core: new scaffolds against malaria disease 43
Totale 10.356
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.834
article - articoli 0
book - libri 0
conference - conferenze 15.976
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.810
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019300 0 0 0 0 0 0 0 0 0 0 189 111
2019/20201.495 85 49 66 162 90 238 195 106 143 148 118 95
2020/20211.461 140 126 87 81 103 62 105 74 229 97 132 225
2021/20221.816 76 60 115 169 84 70 103 86 39 215 468 331
2022/20232.990 288 328 109 290 215 668 260 198 252 90 167 125
2023/20241.389 205 212 114 87 121 189 190 80 25 159 7 0
Totale 11.722